• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—July 2

    OmniGuide Awarded FDA Clearance for RevoLix Hybrid Thulium Laser

    Pancryos Forges License Agreement for Microencapsulation Device

    FDA Awards IDE Approval to SELUTION SLR Drug-Eluting Balloon

    Matt Rainville Joins Bigfoot Biomedical as Chief Commercial Officer
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Theranos Fraud Trial, Part II: The Blame Game Continues

    An Update on Surgical Robotics

    Letting the Light In: How Failure Analysis is the Cornerstone of Success

    Three Talent Strategies to Attract High-Demand Skills

    The Advantages of Bioburden Screening for Sterilization Validation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Concise Engineering

    JBC Technologies

    Arthur G. Russell Co. Inc., The

    Xact Wire EDM Corp.

    Cirtec Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    ‘Right to Repair’: Separating Fact from Fiction

    Taking a Holistic Approach to Decentralized Clinical Trials (DCTs)

    Investment in Health Startups Drops

    The Power of Leveraging Customer Relationships

    Cost Effective & Efficient Wire EDM Techniques
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Concise Engineering

    JBC Technologies

    Arthur G. Russell Co. Inc., The

    Xact Wire EDM Corp.

    Cirtec Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Second Sight Appoints Chief Operating Officer

    New hire has vast experience in the medtech industry.

    Second Sight Appoints Chief Operating Officer
    The Argus II Retinal Prosthesis System is also known as the bionic eye or the retinal implant. It is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals with severe to profound Retinitis Pigmentosa. Image courtesy of Second Sight Medical Products.
    Related CONTENT
    • Second Sight Touts Cortical Prosthesis Study Results
    • Scott Dunbar Named Acting CEO of Second Sight Medical Products
    • Second Sight Aborts Business Combination with Pixium Vision
    • FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    • FEops Strengthens Management Team
    Business Wire10.09.18
    Second Sight Medical Products Inc., a developer, manufacturer, and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, has appointed Pat Ryan as chief operating officer (COO), effective immediately. In this newly created role, Ryan will assume responsibility for Research and Development, Manufacturing, Planning & Materials, Quality Assurance, and Information Technology. He will report to Will McGuire, Second Sight’s president and CEO.
     
    “Pat brings a wealth of knowledge from both large and small medical device firms, and we are delighted to welcome him to the Second Sight team. He has successfully led organizations in multiple regions of the world including COO roles at several public medical device companies. Pat’s deep knowledge in manufacturing, quality assurance and R&D will be especially critical as Second Sight continues to develop the Orion Cortical Visual Prosthesis System (Orion) and prepares for significantly higher manufacturing volumes in future years,” said McGuire.
     
    Ryan’s previous roles include serving as chief operations officer at Synaptive Medical, and COO at Lucerno Dynamics and Insulet Corporation. He also served as COO and president, International, at Alphatec Spine. Earlier in Ryan’s career, he held multiple leadership positions at Guidant and Abbott Vascular, including divisional vice president of Worldwide Operations at Abbott Vascular as well as vice president and managing director for Guidant’s manufacturing facility in Ireland. Following his graduation from the United States Naval Academy with a bachelor of science degree in economics, Ryan served as an officer in the U.S. Navy. He then received a master of science degree in petroleum management from the University of Kansas.

    “Pat has the perfect background to ready Second Sight for an exciting future with Orion. His strong leadership in key areas will be invaluable, as we move the Orion clinical and development programs forward and prepare for success in a market that includes hundreds of thousands of potential patients worldwide,” said Gregg Williams, board chairman.
     
    The company recently completed enrollment of the first five subjects, ahead of schedule, with Orion at the Ronald Reagan UCLA Medical Center (UCLA) and the Baylor College of Medicine in Houston (Baylor) as part of Second Sight’s early feasibility clinical study. All five subjects have had their Orion systems activated, and all subjects reported seeing light from virtually all electrodes and stimulation parameters are within expected ranges. As a result of these successes, the company is now progressing with more complex testing involving real-time video input. Over the coming months, Second Sight intends to collect additional important clinical and performance data to support the safety and efficacy of this breakthrough device.
     
    “I am thrilled to join Second Sight at this exciting time and to help the organization build on its significant achievements to date. I look forward to working with Will and the rest of the team to scale the infrastructure and team necessary for the commercial success of Orion, and to enhance shareholder value,” said Ryan.
     
    Second Sight Medical Products Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the company is committed to developing new technologies to treat the broadest population of sight-impaired individuals.
     
    Second Sight’s Argus II Retinal Prosthesis System is the only U.S. Food and Drug Administration (FDA)- and CE Mark-approved device for treating retinitis pigmentosa, with proven implant durability of multiple years. In 2016, the company published five year results. Today, several Argus II devices have been implanted and operational in humans for more than 10 years. The company is developing the Orion I Visual Cortical Prosthesis which is intended to provide useful artificial vision to individuals who are blind due to various causes. The company’s U.S. headquarters is in Los Angeles, Calif., and its European headquarters is in Lausanne, Switzerland.
     
    Affecting one in 4,000 individuals worldwide, retinitis pigmentosa (RP) is a rare, inherited genetic disorder that damages retinal cells called photoreceptors. Photoreceptors absorb and convert light into electrical signals sent to other retinal cells, then through the optic nerve to the brain which processes them into images. Common early symptoms of RP, often experienced in childhood, include difficulty seeing at night and lost peripheral vision. Later, the disease may lead to blurring of vision, tunnel vision, loss of central vision or loss of the ability to see colors. In many cases, severe vision problems occur in early adulthood. RP may impact an individual’s ability to perform essential tasks of daily living such as reading, driving, walking without assistance, or recognizing faces and objects.
     
    The Argus II Retinal Prosthesis System is an established, FDA- and CE mark-approved retinal implant that delivers a useful form of artificial vision to individuals who are blind due to severe to profound retinitis pigmentosa (RP). The Argus II works in place of lost photoreceptor cells and sends electrical pulses to remaining viable retinal cells to induce visual perception. The system works by converting images captured by a miniature video camera mounted on glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses stimulate the retina's remaining cells, enabling perception of patterns of light in the brain. The user learns to interpret these visual patterns in order to regain some visual function. The Argus platform, which leverages the unique, patented design of its 60-contact array, is supported by more than 10 years of clinical experience and has been evaluated in multiple peer reviewed publications. Argus II was also the first retinal neuromodulation prosthesis to receive widespread commercial approval and is presently available at more than 50 leading medical centers in North America, Europe, the Middle East, and Asia.
     
    Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. The Orion System is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A feasibility study of the Orion I device is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and Baylor College of Medicine in Houston. No published in-human data is available yet for the Orion system. Based on the results of this first in-human testing of the Orion I cortical stimulation device, the company anticipates initiation of the next study in 2019.
    Related Searches
    • medtech
    • assurance
    • insulet corporation
    • it
    Suggested For You
    Second Sight Touts Cortical Prosthesis Study Results Second Sight Touts Cortical Prosthesis Study Results
    Scott Dunbar Named Acting CEO of Second Sight Medical Products Scott Dunbar Named Acting CEO of Second Sight Medical Products
    Second Sight Aborts Business Combination with Pixium Vision Second Sight Aborts Business Combination with Pixium Vision
    FDA Approves Second Sight FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    FEops Strengthens Management Team FEops Strengthens Management Team
    6. Abbott Laboratories 6. Abbott Laboratories
    15 Years of Consi-stent Medtech Progress 15 Years of Consi-stent Medtech Progress
    Former Board Chairman Resigns From Second Sight Medical Products Former Board Chairman Resigns From Second Sight Medical Products
    Second Sight Appoints Chief Financial Officer Second Sight Appoints Chief Financial Officer
    Second Sight Medical Products Appoints Board Chairman Second Sight Medical Products Appoints Board Chairman

    Related Breaking News

    • Second Sight Touts Cortical Prosthesis Study Results

      Second Sight Touts Cortical Prosthesis Study Results

      Preliminary findings show participants benefit from Orion Visual Cortical Prosthesis.
      Business Wire 07.14.21

    • Scott Dunbar Named Acting CEO of Second Sight Medical Products

      Scott Dunbar Named Acting CEO of Second Sight Medical Products

      Temporary leader has been with the company nearly 20 years.
      Michael Barbella, Managing Editor 05.14.21

    • Second Sight Aborts Business Combination with Pixium Vision

      Second Sight Aborts Business Combination with Pixium Vision

      Pixium said it would take all necessary means—including legal measures—to claim compensation.
      Sam Brusco, Associate Editor 04.05.21


    • FDA Approves Second Sight

      FDA Approves Second Sight's Argus 2s Retinal Prosthesis

      Features significantly more processing power.
      Sam Brusco, Associate Editor 03.08.21

    • Cardiovascular
      FEops Strengthens Management Team

      FEops Strengthens Management Team

      Company adds two former Abbott executives to its management team.
      Business Wire 08.01.18

    Loading, Please Wait..

    Trending
    • How To Overcome The Top 6 Medical Device Manufacturing Challenges
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • AI-Enabled SKOUT Device Improves Colorectal Cancer Screening
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • 7 Steps To Create Your Own Medical Device Marketing Plan
    Breaking News
    • MPO's Most-Read Stories This Week—July 2
    • OmniGuide Awarded FDA Clearance for RevoLix Hybrid Thulium Laser
    • Pancryos Forges License Agreement for Microencapsulation Device
    • FDA Awards IDE Approval to SELUTION SLR Drug-Eluting Balloon
    • Matt Rainville Joins Bigfoot Biomedical as Chief Commercial Officer
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • OEMs Seek Molders Offering Timely Techniques
    • Robotic Surgery: Cutting Through to the Latest
    • Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Pharmavite Expands in Ohio with $200 Million Investment
    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
    Coatings World

    Latest Breaking News From Coatings World

    Azelis Acquires Chemical Partners, Strengthens Leadership in Africa and Middle East
    Emmanuelle Bromet Named Arkema Sustainable Development VP
    ROSS Planetary Dual Dispersers Have Unique Processing Flexibility
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—July 2
    OmniGuide Awarded FDA Clearance for RevoLix Hybrid Thulium Laser
    Pancryos Forges License Agreement for Microencapsulation Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bayer Opens New Research and Innovation Center at Kendall Square
    Lonza Names Maria Soler Nunez as Head, Group Operations
    Eurofins DiscoverX Opens Shanghai Office
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Dexlevo Introduces Beauty Treatment technique, ‘GOURI’
    Revision Skincare Exec Wins Ernst & Young Entrepreneur of the Year
    Latest Updates About Cosmoprof North America
    Happi

    Latest Breaking News From Happi

    SCOTUS EPA Ruling Won’t Impact General Regulatory Authority
    Toning Collection For Zero-Brass Blondes is New at Colorproof
    Esthetician Studio Beauty Concepts Files Trademark Infringement Lawsuit Against Kim Kardashian and Coty, Inc.
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Flint OPS, Xerox and MNYPIA Top This Week’s News
    Azelis Acquires Chemical Partners, Adds to Leadership in Africa and Middle East
    International Paper Publishes 2021 Sustainability Report
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    UPM Raflatac boosts operations in US, All4Labels returns to HP and more
    Fedrigoni Self-Adhesives to exhibit at Labelexpo Americas for first time
    CELAB Europe wins Paper Recycling award
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Glatfelter, Blue Ocean Closures Partner with Absolut
    What You’re Reading on Nonwovens-Industry.com
    Daio, Livedo Partner to Recycle Diapers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—July 2
    NuVasive Inc. Opens Singapore Experience Center
    Pedicle Screw Systems Market to Top $3B in 2027
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Identiv, and Japan Display Top This Week’s Stories
    Epishine is Building a New Solar Cell Factory in Linköping, Sweden
    Toppan Establishes CVC Fund and Investment Management Company in the US

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login